AA
HAE icon

ALPS Advisors’s Haemonetics HAE Stock Holding History

ALPS Advisors’s Portfolio HAE Stock Details HAE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-3,520
Closed -$301K – 1015
2023
Q4 		$301K Sell
3,520
-200
-5% -$17.3K ﹤0.01% 852
2023
Q3 		$333K Buy
+3,720
New +$332K ﹤0.01% 727
2020
Q3 		– Sell
-6,369
Closed -$570K – 876
2020
Q2 		$570K Buy
6,369
+3,674
+136% +$371K 0.01% 434
2020
Q1 		$269K Buy
+2,695
New +$292K ﹤0.01% 519

Other funds holding HAE

Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Neuberger Berman Group
Neuberger Berman Group New York $131B AUM 28.36% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
RA
Royce & Associates New York $10.1B AUM 42.88% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

ALPS Advisors's HAE Position: Q1 2024 in Review

ALPS Advisors sold out of Haemonetics (HAE) in Q1 2024, closing a stake of 3,520 shares — an estimated $301K sold.

ALPS Advisors first reported a position in HAE in Q1 2020 and held it in 4 quarters. The position peaked at $570K in Q2 2020. 298 funds tracked by Wall St. Rank hold HAE as of Q1 2024.

  • ALPS Advisors reported no remaining Haemonetics position as of Q1 2024 after selling out during the quarter.
  • ALPS Advisors sold 3,520 Haemonetics shares in Q1 2024, an estimated $301K.
  • ALPS Advisors first reported a position in Haemonetics in Q1 2020 and held it in 4 quarters.
  • ALPS Advisors's Haemonetics position peaked at $570K in Q2 2020.
  • 298 funds tracked by Wall St. Rank held Haemonetics as of Q1 2024.

Based on ALPS Advisors's 13F filing for Q1 2024, filed 14 May 2024.